Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and aBRCAmutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy-Reference-Cited by-同舟云学术

Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and aBRCAmutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy

Published:2016-04-08 Issue:12 Volume:122 Page:1844-1852
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Matulonis Ursula A.¹,Harter Philipp²,Gourley Charlie³,Friedlander Michael⁴,Vergote Ignace⁵,Rustin Gordon⁶,Scott Clare⁷,Meier Werner⁸,Shapira-Frommer Ronnie⁹,Safra Tamar¹⁰,Matei Daniela¹¹,Fielding Anitra¹²,Spencer Stuart¹²,Parry David¹²,Grinsted Lynda¹²,Ledermann Jonathan A.¹³

Affiliation:

1. Dana-Farber Cancer Institute; Boston Massachusetts

2. Kliniken Essen-Mitte; Essen Germany

3. Edinburgh Cancer Research UK Centre; University of Edinburgh; Edinburgh United Kingdom

4. Prince of Wales Hospital; Randwick New South Wales Australia

5. University of Leuven; Leuven Belgium

6. Mount Vernon Hospital; Northwood United Kingdom

7. Royal Melbourne Hospital; Melbourne Victoria Australia

8. Evangelical Hospital; Dusseldorf Germany

9. Chaim Sheba Medical Center; Tel Hashomer Israel

10. Tel Aviv Sourasky Medical Center; Tel Aviv Israel

11. Indiana University School of Medicine; Indianapolis Indiana